MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

Nivolumab (anti-PD-1)

产品活性：Nivolumab (anti-PD-1) 是一种 PD-1 人源类 IgG4 抗体类抑制剂，用于晚期（转移性）非小细胞肺癌的研究。

研究领域：Immunology/Inflammation

作用靶点：PD-1/PD-L1

In Vitro: Nivolumab (anti-PD-1) binds to CHO cells expressing PD-1 with an EC₅₀ of 1.66 nM, but does not bind to the parental CHO cell line. Nivolumab (anti-PD-1) binds to PD-1 on activated T cells with an EC₅₀ of 0.64 nM. Nivolumab (anti-PD-1) also inhibits the interaction between PD-1 and its ligands, PD-L1 and PD-L2, with IC₅₀ values of 2.52 and 2.59 nM, respectively. Nivolumab (anti-PD-1) (1.5 ng/mL) can enhance T-cell reactivity in the presence of a T-cell receptor stimulus.

In Vivo: Nivolumab (anti-PD-1) (10 and 50 mg/kg, i.v.) is well tolerated in cynomolgus monkeys. Serum chemistry changes are limited to a reversible 28% decrease in T3 at week 13 in females treated with 50 mg/kg. T4 and TSH levels are unchanged. In males treated with 50 mg/kg, there are no changes in T3, T4, or TSH levels. Nivolumab (anti-PD-1) exposure increases in an approximately dose-proportional manner between 10 and 50 mg/kg, with no substantial sex differences noted.

相关产品：Atezolizumab  |  Pembrolizumab  |  Nivolumab  |  BMS-1  |  BMS-202  |  Tomivosertib  |  Avelumab  |  Durvalumab  |  CA-170  |  Fraxinellone  |  BMS-1166  |  BMS-1001 hydrochloride  |  INCB086550  |  Camrelizumab  |  AUNP-12 TFA  |  BMSpep-57 hydrochloride  |  PD-1/PD-L1-IN-9  |  PROTAC PD-1/PD-L1 degrader-1  |  TPP-1  |  Sulfamethoxypyridazine  |  Human PD-L1 inhibitor V TFA  |  PD-1-IN-17  |  PD-1/PD-L1-IN-10  |  ARB-272572  |  BMS-8  |  D18

品牌介绍:
•   MCE (MedChemExpress) 拥有数百种全球独家化合物，我们致力于为全球科研客户提供最新最全的高品质小分子活性化合物；
•   10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种顶级期刊及制药专利收录了MCE客户的科研成果；
•   专业团队跟踪最新的制药及生命科学研究进展，为您提供全球最新的活性化合物；
•   与世界各大制药公司及知名科研机构建立了长期的合作。